Competitive landscape · Expert interview

How Korean drug makers take share from a heart-drug originator after patent expiry, from first month to clinic floor

Format
Modelled interview
As of
October 2026
Market
South Korea
Industry
Pharmaceuticals
Length
≈ 30 min read
Hanmi PharmaceuticalChong Kun DangOrganonBoryungViatrisJeil PharmaceuticalJinyang PharmJW PharmaceuticalAhn-Gook PharmaceuticalNovartisMinistry of Health and WelfareMinistry of Food and Drug SafetyUBIST
Modelled interview. Built from KIRA's face-to-face and telephone interviews with marketing, sales and product-development managers at Korean domestic drug makers and with drug-pricing officials, set in today's market. How the trade works comes from what those people told our analysts; every figure comes from a public source dated 2024-2026, marked next to the answer.

Summary

  • After expiry the market fills with labels, not factories: of 113 companies selling atorvastatin/ezetimibe, only 11 make their own product, and the 75 mg clopidogrel tablet has more than 120 same-strength generics. 1 2
  • The first month is worth the most: Chong Kun Dang's equivalent product and its 22 authorized generics were listed one month ahead of 88 others, and Chong Kun Dang-made products now hold 23.5% of the market against the original's 32.1%. 1 3
  • Clinics decide the outcome: they were 58.5% of the sales targets in contract sales agreements, and the domestic makers' clinic-heavy sales forces are their main weapon, while trial-site university hospitals are the first formulary wins. 2 4 5
  • The price floor is moving: newly listed generics now price at 45% of the original instead of 53.55%, and the stepped cut now starts at the 13th product for a formulation, which thins the crowd of late entrants. 6 7
  • Originators that fight back with new strengths, data and partners can keep growing: Livalozet's prescriptions rose 19% even as its share fell from 66% to 52%, and Atozet moved its co-promotion to Boryung. 6 1 8
  • Promotion is under tighter watch: 20,014 contract sales organizations are now registered, average commissions ran at 42.9%, and the safer route is clinical data, symposia and bundles with the firm's own cardiovascular line. 2 9 10

Transcript

01One molecule, a hundred labels

KAKIRA Analyst

You manage a hypertension and lipid portfolio at a Korean domestic drug maker. What should a foreign company understand first about what happens here when a heart drug loses its patent?

EXExpert

That it is not a handful of rivals, it is a crowd, and most of the crowd does not own a factory for that product. Take the atorvastatin and ezetimibe combination. There are 113 domestic companies in that market, only 11 make their own product, and the other 102 came in through contract manufacturing. Two manufacturers each make it for more than 20 client companies. The same pill, with different boxes and different sales teams. 1

The health ministry's own audit data this autumn put it even more bluntly. For the 75 mg clopidogrel tablet, more than 120 generic products with the same ingredient and strength are on the market. Across the products where the ministry could confirm the rate, the average commission paid to contract sales organizations was 42.9%, and 140 contracts were at 50% or higher. 2 When you see that, you understand that after expiry the fight is less about the molecule and more about who carries it into the doctor's room. 4

KAKIRA Analyst

So where does a mid-sized maker like yours make money in that crowd?

EXExpert

By being early, by owning the factory if we can, and by putting the product inside a family. The crowd shares the volume, but a firm that makes the product for more than 20 others earns twice: on its own box and on everybody else's. Chong Kun Dang-made products took 23.5% of the atorvastatin and ezetimibe combination market in the second quarter, against 32.1% for the original Atozet. 1

The other route is to build your own combination before the patent wave arrives. Look at Hanmi. Its rosuvastatin and ezetimibe combination, Rosuzet, did KRW 227.9 billion in prescriptions last year, and its Amozaltan family did KRW 145.4 billion, out of KRW 1.0836 trillion of outpatient prescription revenue. 11 That is a domestic company that stopped waiting for other people's patents to expire and made the combinations doctors wanted. Every product manager in my company has that slide somewhere. 10

02The first month decides

KAKIRA Analyst

When a patent is about to expire, how do you and your competitors plan the launch?

EXExpert

Everybody believes the first one in takes most of the market, so the whole industry is either racing to be first or quietly watching whoever is first. The later entrants wait for the first launch's numbers, then set their price and their story. In meetings we say it half as a joke: whoever launches first gets the market, the rest of us read his numbers. 3

The atorvastatin and ezetimibe case is the one we all study. Chong Kun Dang got approval for its own equivalent product after a clinical trial, 22 companies got authorized generics based on it, and they were listed for reimbursement one month ahead of the 88 other generics. 1 One month sounds like nothing. In a clinic, it is the month the doctor switches his patients, and patients on a heart pill do not switch twice if they are stable. 3

KAKIRA Analyst

And if somebody wins a patent challenge, is there a formal head start?

EXExpert

Yes, on paper. The first generic maker that successfully challenges a patent can get nine months of exclusivity, but it must be the first to file for approval and also file an invalidation trial or a negative scope action. I say on paper because winning in court is not the same as launching. 12 13

The heart-failure drug Entresto is the example everybody in cardiovascular follows. It had KRW 79.4 billion of outpatient prescriptions last year, up from KRW 32.4 billion in 2021. More than 20 companies challenged its 5 patents and won at the Supreme Court, yet generic approvals are still at 0, because the regulator keeps asking for documents on the cocrystal structure. 13 So I tell my bosses: a patent win is a ticket to the queue, not a launch date. 3

03Clinics first, hospitals through the trial sites

KAKIRA Analyst

Who do you target first after launch, the clinics or the big hospitals?

EXExpert

Clinics, the 의원 (uiwon), the neighbourhood doctor's office where most blood-pressure and cholesterol patients actually get their monthly prescription. That is where the domestic makers are strongest. We run clinic-heavy sales forces, several clinic reps for every hospital rep, and that is our main weapon against the originator. 4 The ministry's contract data shows where the outsourced sales effort goes too: clinics were 58.5% of the sales targets, general hospitals and larger institutions 17.6%, and hospitals 14.7%. 2

The patient pool makes the clinic the obvious place. About 13 million Korean adults have hypertension, 10.9 million received antihypertensive prescriptions in 2022 and 44% of regimens were dual therapy. 14 Dual therapy is exactly where a combination pill fits, and it is a conversation with a clinic doctor who sees the same patients every month. 10

KAKIRA Analyst

But the university hospitals still matter?

EXExpert

They matter for the name. A clinic doctor likes to hear that the professor down the road uses the drug. The trick we inherited from older product managers is to place clinical trials in the most prestigious university hospitals, because the trial site is the natural first hospital to put the drug on its formulary afterwards. The downside is that the top hospitals run several competing trials at once, so trial costs go up. 5

And remember that national reimbursement listing is only the first gate. Each hospital has its own drug committee, the DC, and listing there is a separate fight. Price matters at that committee as well, not only in how much the drug is used later. 15 A company without strong hospital coverage usually finds a partner to cover the larger hospitals rather than building a team from zero. 4

04The price floor keeps moving

KAKIRA Analyst

How does pricing work for a generic or a combination entering after expiry?

EXExpert

Until this year the reference point was simple. First generics were priced at 59.5% of the originator's pre-expiry price, and the originator took a 30% cut in its first year after generic entry. 16 Generics and the off-patent original then settled at 53.55% of the old originator price. 7

That changed this spring. The reform approved in March cuts the base rate for newly listed generics from 53.55% to 45%, and the stepped reduction that used to start at the 20th generic for a formulation now starts at the 13th. 7 The new rate applies to newly listed generics from October. 6 For a company like mine, the 13th position matters more than the 45%. 7 6 It means the tail of the crowd, the companies who were happy to be one more label at the back, may stop coming. 3

KAKIRA Analyst

Does the regulator push back on your price filings?

EXExpert

Not much, if you are reasonable. What the pricing officials told people in our industry for years still holds in my experience: they rely largely on the documents you submit, a moderately priced file goes through easily, and it is the expensive one they look at hard. So most of us price modestly at listing and fight on everything else. 17

There is still room to choose a position. One maker will compete on corporate image and price a little higher, while a generic specialist goes in low. 18 I cannot tell you our internal numbers, and every molecule is different, but the higher position only works if your reps can get into the clinic with something more to say than the price. 4

05How the originator fights back

KAKIRA Analyst

What does an originator do when the crowd arrives?

EXExpert

The good ones do not just cut price. They bring outcome data, new strengths or indications, and they cut price selectively where it hurts us most. 8 The pitavastatin and ezetimibe combination is a live case. The follow-on products' share rose from 34% to 48%, and the original Livalozet fell from 66% to 52%, but Livalozet's own prescriptions still grew 19%. 6 The follow-on makers launched a low-dose 1/10 mg version first, and the originator answered with its own low-dose product. 6 That is the defence in one picture: give the doctor a new strength so he has a reason to stay. 8

KAKIRA Analyst

And partnerships? I hear originators sometimes change their local partners.

EXExpert

All the time, and that is part of the competitive map too. Chong Kun Dang co-promoted Atozet with Organon from 2016, and Boryung has now become the new marketing partner, while Chong Kun Dang makes its money on the generics. 1 Another original brand house, Viatris, joined the marketing of Jeil's Lipitor Plus, a combination built around its own statin. 1 A partner's sales team can switch sides, so when an originator picks a Korean partner it is really picking whose clinic reps carry its brand. 4

06Promotion under the new rules

KAKIRA Analyst

How has promotion changed with the rules on rebates and contract sales?

EXExpert

Contract sales organizations were brought under the rebate ban and the expenditure-reporting duty in 2021, and since October 2024 they must be registered. There are 20,014 of them registered now. For a product manager that means the outsourced channel is no longer a black box you can pretend not to see. If the commission is very high, people ask what it pays for. 2 9

The older generation lived through the same turn. After official warnings over illegal support, firms cut sponsorship and leaned on clinical data instead, and everybody expected rebates to become less usable. 9 What works now is boring and legal: a clean study, symposia, the circulation society's meetings, and a package with our other cardiovascular drugs so the rep has three reasons to visit instead of one. 10

KAKIRA Analyst

You mentioned building a team. Where do the people come from?

EXExpert

From the competition, mostly. When a firm opens a new category it hires reps and managers with cardiovascular experience from its rivals, because a rep who already knows the cardiologists and the clinic doctors is worth months of training. It is not polite, but nobody is surprised. 19

One more thing about the numbers you read in the press. When a company announces a big first-year sales target, read it as advertising. Its own sales staff usually think it is unrealistic. The real targets live in a spreadsheet nobody publishes. 20

07Advice to a newcomer, and what worries me

KAKIRA Analyst

A Japanese or Chinese maker wants to enter Korea's cardiovascular market after the next big patent expiry. What should it do?

EXExpert

Do not plan to be one more label at the back of the queue. Under the new rule the late entrants get a lower price, and the stepped cut now starts at the 13th product. 7 Either be early with a partner who already has a clinic sales force, or bring something the crowd cannot copy quickly: a combination, a new strength, a smaller tablet, real data. 4 8

Ahn-Gook's Pevarozet is a nice example. It is a self-developed product that promotes a smaller tablet, and Ahn-Gook also manufactures the same-ingredient products for several other companies. 6 Find a domestic partner with a factory and a clinic team, start the trial at a university hospital that will put you on its formulary, and accept that some doctors here prefer local products. 5 21

KAKIRA Analyst

What would change your mind about this playbook, and what worries you?

EXExpert

If the new pricing rule really thins the crowd, the first-mover game may change. With fewer labels per molecule, the products that differ in dose, combination or data could matter more than speed. I would change my mind about racing for the first month if I saw a late entrant with a real difference overtake the early ones. 3 8

What worries me is the gap between winning a patent and getting a product to the clinic. The Entresto challengers won in court and still have 0 approvals. 13 And the margin for a crowded generic gets thinner every year while contract sales commissions averaged 42.9%. 2 A company that builds its whole plan on being first, without a product doctors want to stay on, can end up very busy and not very profitable. 3

Sources and basis

  1. 1
    UBIST data reported by Dailypharm: atorvastatin/ezetimibe outpatient prescriptions totaled KRW 207.3 billion in the first half of the year, up 14.0%; more than 100 domestic companies entered almost simultaneously from 2021; Chong Kun Dang's Lipilouzet was approved in October 2020 after a clinical trial showing equivalence, 22 companies got authorized generics based on it, listed in April 2021, one month ahead of 88 other generics listed in May; 113 domestic companies are in the market, only 11 manufacture their own product and the remaining 102 entered through contract manufacturing; Jinyang Pharm and Chong Kun Dang each manufacture for more than 20 client companies; in Q2 generics totaled KRW 71.9 billion, 67.9% of the market, the original Atozet KRW 33.9 billion with a 32.1% share, and Chong Kun Dang-manufactured products 23.5%; Chong Kun Dang had co-promoted Atozet with Organon since 2016 and Boryung became the new marketing partner; Viatris, which markets Lipitor, joined the marketing of Jeil Pharmaceutical's Lipitor Plus
    Public source · Dailypharm, 12 Aug 2026 (UBIST data) · link
  2. 2
    Health Ministry data submitted to a lawmaker for the parliamentary audit: 20,014 CSOs (contract sales organizations) are registered; 212 of 286 pharmaceutical and import companies submitted consignment contract data, about 980,000 contracts; clinics were the top CSO sales target at 58.5%, followed by general hospitals and larger institutions at 17.6% and hospitals at 14.7%; the average commission rate across 446 products with confirmed rates was 42.9%, 140 contracts (31.4%) had rates of 50% or higher and the highest was 60%; for the 75 mg clopidogrel tablet more than 120 generic products with the same active ingredient and strength were distributed in South Korea; CSOs were added to the rebate ban and expenditure-reporting requirement in 2021 and the registration system took effect in October 2024
    Public source · The Asia Business Daily, 7 Oct 2026 · link
  3. 3
    Local makers expect the first entrant to win most of the share, so later entrants watch the first launch's numbers and then set their price and strategy
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers
  4. 4
    Clinic-heavy sales forces, with several clinic reps for every hospital rep, are the domestic makers' main weapon; firms without strong hospital coverage ally with a partner to cover the larger hospitals
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers
  5. 5
    Companies place their clinical trials in the most prestigious university hospitals so that the trial sites later list the drug on their formularies; top hospitals run several competing trials at once, which raises trial costs
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers
  6. 6
    UBIST data reported by Dailypharm: pitavastatin/ezetimibe outpatient prescriptions were KRW 70.9 billion in Q3 2026, up 42% year on year; KRW 191.1 billion cumulative to Q3, above KRW 185.4 billion for all of 2025; the market was created when JW Pharmaceutical launched Livalozet in October 2021, and same-ingredient follow-on products appeared from August 2023; the follow-on products' share rose from 34% in Q1 2025 to 48% in Q3 2026 while Livalozet fell from 66% to 52%, although Livalozet's own prescriptions grew 19%; Ahn-Gook Pharmaceutical's self-developed Pevarozet promotes a smaller tablet, and Ahn-Gook contract-manufactures the same-ingredient products of several other companies; follow-on makers launched low-dose 1/10 mg products first and JW Pharmaceutical answered with its own low-dose product; from October 2026 newly listed generics are priced at 45% of the original instead of 53.55%
    Public source · Dailypharm, 3 Nov 2026 (UBIST data) · link
  7. 7
    The Health Insurance Policy Deliberation Committee approved the drug-pricing reform on 26 March 2026: the base rate for generics and patent-expired originators falls from 53.55% to 45% of the pre-generic originator price for newly listed drugs; the stepped reduction to 85% of the preceding lowest price, which used to start at the 20th generic for a formulation, now starts at the 13th; a patent-expired originator with generics listed keeps 70% in its first year
    Public source · Shin & Kim newsletter, 14 Apr 2026 · link
  8. 8
    Originators defend with clinical outcome data, new strengths or indications and selective price cuts
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers
  9. 9
    After official warnings over illegal support, firms cut sponsorship and leaned on clinical data instead; rebates were expected to become less usable
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers
  10. 10
    Entrants plan joint promotion and package deals with their other cardiovascular drugs, and sponsor the national circulation society's conferences and seminars to build doctor networks
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers
  11. 11
    Hanmi Pharmaceutical 2025: revenue KRW 1.5475 trillion; outpatient prescription revenue KRW 1.0836 trillion; Rosuzet (rosuvastatin/ezetimibe) prescription sales KRW 227.9 billion, up 8.4%; Amozaltan Family sales KRW 145.4 billion
    Public source · The Asia Business Daily, 5 Feb 2026 · link
  12. 12
    Korea provides a generic exclusivity incentive of nine months to the first generic manufacturer that successfully challenges a patent; it must be the first to submit a marketing application and file a patent invalidation trial or a negative scope action (Article 50 (7) of the Pharmaceutical Affairs Act)
    Public source · Bae, Kim & Lee, Chambers Life Sciences and Pharma IP 2026, South Korea chapter · link
  13. 13
    UBIST data reported by Dailypharm: Novartis's heart-failure drug Entresto had KRW 79.4 billion of outpatient prescriptions last year, up from KRW 32.4 billion in 2021; more than 20 companies filed challenges against its 5 patents from January 2021 and the generic makers won at the Supreme Court; about 10 challengers applied for approval, yet generic approvals stand at 0, with the regulator asking for supplementary documents because of the drug's cocrystal structure
    Public source · Dailypharm, 20 Jan 2026 · link
  14. 14
    An estimated 30% of Korean adults (13 million) have hypertension; 10.9 million received antihypertensive prescriptions and 8.1 million were in continuous treatment in 2022; regimens were monotherapy 40%, dual therapy 44% and three or more drugs 16%
    Public source · Korea Hypertension Fact Sheet 2024, Clinical Hypertension vol. 31, 2025 · link
  15. 15
    Listing on each hospital's formulary is a separate gate after national listing, and trial-site hospitals are the natural first targets; drug price affects whether a hospital lists a drug as well as how much it is used
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers and drug-pricing officials
  16. 16
    Under the Korean system, first generics are priced at 59.5% of the originator's pre-expiry NHI price and the originator takes a 30% cut in the first year after generic entry
    Public source · GlobalData analyst comment via Pharmaceutical Technology, 12 Feb 2026 · link
  17. 17
    Pricing officials rely largely on the documents companies submit; moderately priced submissions go through easily, while expensive ones are examined hard
    KIRA field interviews · KIRA field interviews, Korean drug-pricing officials
  18. 18
    Different makers choose different positions after expiry: one competes on corporate image and prices slightly higher, while a generic specialist goes in low
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers
  19. 19
    Firms poach reps and managers with cardiovascular experience from rivals to build a new category team
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers
  20. 20
    Publicly announced sales targets are inflated as a form of advertising, and the firm's own sales staff see them as unrealistic
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers
  21. 21
    Some domestic doctors show a preference for local products, which helps local makers against the originator
    KIRA field interviews · KIRA field interviews, Korean domestic drug makers

Key points

Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.

More on Prescription drugs in South Korea